id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2012-D-1120-0012,FDA,FDA-2012-D-1120,"Vaginal Microbicides: Development for the Prevention of Human
Immunodeficiency Virus Infection; Guidance for Industry",Other,Guidance,2014-11-19T05:00:00Z,2014,11,2014-11-19T05:00:00Z,,2024-11-12T05:33:33Z,,1,0,0900006481938be8
FDA-2012-D-1120-0011,FDA,FDA-2012-D-1120,"Vaginal Microbicides: Development for the Prevention of Human
Immunodeficiency Virus Infection; Guidance for Industry; Availability",Notice,Notice of Availability,2014-11-19T05:00:00Z,2014,11,2014-11-19T05:00:00Z,,2014-11-19T17:02:36Z,2014-27287,0,0,0900006481937e09
FDA-2012-D-1120-0002,FDA,FDA-2012-D-1120,Draft Guidance for Industry on Vaginal Microbicides: Development for the Prevention of Human Immunodeficiency Virus Infection,Other,Guidance,2012-11-23T05:00:00Z,2012,11,2012-11-23T05:00:00Z,2013-02-22T04:59:59Z,2019-06-19T19:40:36Z,,0,0,09000064811717f6
FDA-2012-D-1120-0001,FDA,FDA-2012-D-1120,Draft Guidance for Industry on Vaginal Microbicides: Development for the Prevention of Human Immunodeficiency Virus Infection; Availability,Notice,Notice of Availability,2012-11-23T05:00:00Z,2012,11,2012-11-23T05:00:00Z,2013-02-22T04:59:59Z,2013-02-22T03:03:44Z,2012-28430,0,0,09000064811718a5